drugset / Trial / NCT00653822

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

NCT00653822

Phase 1 Completed 75 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blind

Summary

The objective of this study is to compare the pharmacokinetic and pharmacodynamic properties and safety profile of alefacept in Caucasian and Japanese healthy subjects

Timeline

Start
2008-03
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic Intravenous

Indications

No indication recorded.